Nextgen Share Discussion Threads

[gammelgaard] 30/4/2012 17:03

With a positive attitude one can get very far - thats my experience. And NGG is surely an interesting company, not to mention its products. Wait and see!

[bobby.ifa] 30/4/2012 15:31

Some mugs like me with cash to burn no doubt.

[andrbea] 30/4/2012 15:09

ngg 10%

30/04/2012 15:06:15 NGG 0.20 O 2,600,000
30/04/2012 15:06:11 NGG 0.20 O 2,600,000
30/04/2012 12:12:38 NGG 0.15 O 1,700,000
30/04/2012 12:12:13 NGG 0.15 O 1,700,000
30/04/2012 11:10:07 NGG 0.14 O 275,000

[bobby.ifa] 30/4/2012 12:53

99% of share holders agreed to the consolidation of 500 shares to 1 at 50p. Watch this sing to 10p over the next 6 months. Consolidation has never helped me in the past.

[bobby.ifa] 16/4/2012 15:30

Surely the company must have something to say here.

[look alive] 02/4/2012 20:05

The problem with Nextgen is that they keep running out of money and issuing 12% Loan Stock with warrants and fat fees attached to fund the losses. There are already enough shares in issue for the entire population of the World to own one each and this more than doubles if the warrants and options are taken into account.

[bobby.ifa] 02/4/2012 18:43

Unloved & overlooked. Not me silly, this stock!

[gobblehoof2] 30/3/2012 15:46

Hi Bobby

To respond to your question - NextGen's share price seems to have gone up on news that it is registering IP for its biomarkers which can diagnose and track the progress of early stage dementia. The news should be on the RNS section of this website if you want to have a look.

[bobby.ifa] 23/3/2012 12:20

This thread is as popular as the Gordon Brown appreciation society.

[bobby.ifa] 23/3/2012 09:15

This has sneaked up nearly 100% in two weeks & seems off everyone's radar. Anyone klnow the reason for the rise?

[stephanie_m] 20/3/2012 16:12

Increased interest in NGG

s

[bobby.ifa] 20/3/2012 16:05

I was offered 26p on a dummy sale of 1 million. Clearly a buyer out there.

[stephanie_m] 20/3/2012 15:50

L2 quietly ticking up - see header

s

[stephanie_m] 16/3/2012 16:41

L2 will be updated in header should the shares become active.

s

[bobby.ifa] 16/3/2012 15:45

Market Makers really want stock, they will pay a premium for my 2 million if I sold them.

[bobby.ifa] 16/3/2012 11:20

Suddenly jumped again. Wierd stock this.

[the_doctor] 15/3/2012 12:55

Amazing to see the price jump on that last IP news

anyone following the sector will know how long it takes to get value out of that

[stephanie_m] 13/3/2012 09:37

UK-Analyst: featuring,Gulf Keystone, Close Brothers and NextGen Group Today (2012-03-13 17:26:55)



"Staying on the topic of disease treatment, NextGen Group (NGG) announced it has filed for intellectual property on a combination of protein biomarkers which have the potential to diagnose cognitive changes in patients with early-stage dementia. The firm believes the product will have a duel purpose, to identify the progression of the disease in patients, but also to aid drug companies in the patient selection process for clinical trials. With more than 36 million people suffering from the disease globally, and almost 500 dementia and cognitive clinical trials currently in progress, the firm believes it is now in a strong position to exploit a huge market. NextGen shares surged 0.025p to 0.225p."

s

[stephanie_m] 13/3/2012 07:26

Tuesday 13 March, 2012


NextGen Group PLC

IP Filings


RNS Number : 2069Z

NextGen Group PLC

13 March 2012






March 13 2012



Issued by NextGen Group Plc



NextGen files for intellectual property on dementia biomarkers



· Intention to pursue IP across multiple dementia areas

· Further studies planned to expand patent portfolio



NextGen Group Plc (AIM: NGG), an AIM listed company providing biomarker discovery services and diagnostic assay development, announces that its subsidiary, NextGen Sciences Dx (NGSDx), has filed for intellectual property (IP) on a combination of protein biomarkers with the potential for diagnosing changes in cognition for patients with early-stage dementia.



Barry McAleer, PhD, CEO of NextGen Sciences Inc and NextGen Sciences Dx, says: "The biomarkers we have identified in cerebrospinal fluid (CSF) have the potential to aid decision-making on how to treat patients who have early-stage dementia (i.e. mild-moderate cognitive impairment), to assist in patient selection for clinical trials and to monitor the effectiveness of drugs in development. It gives us an immediate foothold in a critical healthcare market."

[gobblehoof2] 23/2/2012 18:08

Sounds like some interesting progress from NextGen.



They've just set up a new subsidiary through which they're ready to file intellectual property in the next six months in the diagnostics areas of Central Nervous System disorders and oncology. They are describing this as a big step forward for the company.